Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Charles River Laboratories (CRL)

NYSE: CRL · Life Sciences Tools & Services · Wilmington, MA

Our rating: Neutral

Neutral reaffirmed at $313.02, moderate conviction, November 5, 2026.

Breaks if: The Neutral call turns Cautious if free cash flow falls below $500M on a trailing twelve-month basis for two consecutive quarterly filings — that would signal the cash-generation thesis is impaired, not just the accounting line. It turns Positive if revenue returns to growth above 3% year-on-year while net income turns positive within the next two quarterly reports, confirming that the cycle has genuinely turned.

Key figures

Market value$15.1B
Revenue, last 12 months$4.0B
Net income, last 12 months$40M
Free cash flow, last 12 months$400M
Price to earnings374.8×
Free cash flow yield2.7%
Dividend yield0.0%
Operating margin4.0%
Return on equity1.2%
Beta to the S&P 5001.31
Volatility, annualized49.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 26, 2026$983M−2.2%$6.86$207M
June 27, 2026$1.0B−2.7%$-0.03$149M
March 28, 2026$996M1.2%$-0.30−$15M
December 27, 2025$994M−0.8%$-5.56$59M
September 27, 2025$1.0B−0.5%$1.10$178M
June 28, 2025$1.0B0.6%$1.06$169M
March 29, 2025$984M−2.7%$0.50$112M
December 28, 2024$1.0B−1.1%$-4.17$84M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.